Project Grant R44GM139441

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $461,701 to Tega Therapeutics Inc. to develop and validate an intracerebroventricular (ICV) enzyme replacement therapy for the treatment of GM1 gangliosidosis, a rare lysosomal storage disease affecting the central nervous system. The key objectives are to engineer cell lines to...

The National Science Foundation (NSF) awarded a $271,443 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to Mammae Biosciences, Inc., a minority-owned, for-profit, woman-owned business and manufacturer, to develop an enzymatic method to produce compounds found in human milk at commercial scale. The goal is to assess an affordable enzymatic process for generating marketable natural compounds usually found in human milk, such as N-acetylglucosamine...

Simmbion LLC was awarded a $255,136 Project Grant from the National Science Foundation's Small Business Technology Transfer program to develop a system for manufacturing drug therapies inside the human body. Over the one-year period from April 2022 to March 2023, the company will genetically engineer symbiotic blood organisms to express and secrete two therapeutic proteins - β-glucocerebrosidase to treat Gaucher's disease and insulin for diabetes treatment. In vitro and in vivo testing will...

Federal Grant Award Summary Biostrategies LC received a $1,558,305 Project Grant award from the National Institute of Neurological Disorders and Stroke under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective September 15, 2025, with completion targeted for August 30, 2027. The award supports completion of Investigational New Drug (IND)-enabling studies to advance development of BIOS-GM1, a novel therapeutic combining gene therapy...

This SBIR Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program seeks to develop a new class of gene therapies that can be delivered more safely, cost-effectively, and at scale for a wide range of serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes in a precise and reversible...

The federal Project Grant award of $283,805 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of a novel cell-free, high-throughput platform to expedite the engineering of enzymes for biocatalytic "BioClick" reactions. The project, undertaken by Invizyne Technologies, Inc., a small disadvantaged business in Monrovia, CA, focuses on establishing an efficient cell-free protein...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 will provide $463,150 to The Regents of the University of California, San Francisco (UCSF) to establish proof-of-concept for enzyme replacement therapy (ERT) as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome (SPLIS), an ultra-rare and often lethal metabolic disorder. The project aims to demonstrate the efficacy of ERT in preserving kidney function and...

Federal Project Grant Award Summary Tega Therapeutics Inc. received a $1.0 million Project Grant award dated August 5, 2025, from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The grant supports research to develop and validate new clinical biomarkers for GM1 gangliosidosis, a rare lysosomal storage disease caused by deficiency of the enzyme beta-galactosidase....

This Project Grant award from the National Institutes of Health's National Human Genome Research Institute provided $768,678 to Molecular Assemblies, Inc. to develop a fully enzymatic oligonucleotide synthesis cycle using engineered template-independent polymerases and a novel phosphate dNTP blocking group. The award supports the goals of the Human Genome Research program (CFDA 93.172) to accelerate genome research and its application to human health. Specifically, the awardee will engineer...

Cooperative Agreement Summary The National Science Foundation (NSF) awarded Novozymes, Inc. a $2.14 million Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective August 1, 2025, through July 31, 2028. This collaborative research initiative focuses on developing advanced enzymatic and computational strategies to enable cost-effective, scalable synthesis of human milk oligosaccharides (HMOs)—complex sugars naturally present in breast...